

# UC Davis

## UC Davis Previously Published Works

### Title

Erratum: Author correction to Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis in vivo [Acta Pharmaceutica Sinica B 11 (2021) 3950-3965].

### Permalink

<https://escholarship.org/uc/item/40w8g551>

### Journal

ACTA Pharmaceutica Sinica B, 13(8)

### ISSN

2211-3835

### Authors

Deng, Linglong

Petrek, Hannah

Tu, Mei-Juan

et al.

### Publication Date

2023-08-01

### DOI

10.1016/j.apsb.2023.07.002

Peer reviewed



Chinese Pharmaceutical Association  
Institute of Materia Medica, Chinese Academy of Medical Sciences

Acta Pharmaceutica Sinica B

[www.elsevier.com/locate/apsb](http://www.elsevier.com/locate/apsb)  
[www.sciencedirect.com](http://www.sciencedirect.com)



## CORRECTION

# Author correction to ‘Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis *in vivo*’ [Acta Pharmaceutica Sinica B 11 (2021) 3950–3965]



Linglong Deng<sup>a,b</sup>, Hannah Petrek<sup>b</sup>, Mei-Juan Tu<sup>b</sup>, Neelu Batra<sup>b</sup>,  
Ai-Xi Yu<sup>a,\*</sup>, Ai-Ming Yu<sup>b,\*</sup>

<sup>a</sup>Department of Orthopaedic Trauma and Microsurgery, Zhongnan Hospital of Wuhan University, Wuhan 430072, China

<sup>b</sup>Department of Biochemistry and Molecular Medicine, UC Davis School of Medicine, Sacramento, CA 95817, USA

The authors regret that there was one incorrect image used within Fig. 4A, 143B cells treated with LSA at 24 h time point, which was obtained from vehicle group but mislabelled as LSA in the publication. In our studies, three biological replicates were included in each treatment group and at least three images were taken for different fields of each sample. We thus selected a correct representative image from the LSA treated 143B cells at 24 h time point to replace that mislabelled image, and the updated

Fig. 4 is provided below. The authors apologize for any inconvenience caused to the journal and readers, while this correction does not affect any results and conclusions. The authors have provided the original data of this figure to Editorial Office, and the corresponding authors or the Editorial Office can be contacted for original data access.

The authors sincerely apologize for any inconvenience caused to the journal and readers.

DOI of original article: <https://doi.org/10.1016/j.apsb.2021.07.027>.

\*Corresponding authors.

E-mail addresses: [yuaixi@whu.edu.cn](mailto:yuaixi@whu.edu.cn) (Ai-Xi Yu), [aimyu@ucdavis.edu](mailto:aimyu@ucdavis.edu) (Ai-Ming Yu).

Peer review under the responsibility of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.

<https://doi.org/10.1016/j.apsb.2023.07.002>

2211-3835 © 2023 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

